{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:04:08Z","timestamp":1777388648791,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62171298"],"award-info":[{"award-number":["62171298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prediction of locoregional treatment response is important for further therapeutic strategy in patients with hepatocellular carcinoma. This study aimed to investigate the role of MRI-based radiomics and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The initial postoperative MRI after locoregional treatment in 100 patients with hepatocellular carcinoma was retrospectively analysed. The outcome was evaluated according to mRECIST at 6 months. We delineated the tumour volume of interest on arterial phase, portal venous phase and T2WI. The radiomics features were selected by using the independent sample t test or nonparametric Mann\u2012Whitney U test and the least absolute shrinkage and selection operator. The clinical variables were selected by using univariate analysis and multivariate analysis. The radiomics model and combined model were constructed via multivariate logistic regression analysis. A nomogram was constructed that incorporated the Rad score and selected clinical variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty patients had an objective response, and fifty patients had a nonresponse. Nine radiomics features in the arterial phase were selected, but none of the portal venous phase or T2WI radiomics features were predictive of the treatment response. The best radiomics model showed an AUC of 0.833. Two clinical variables (hCRP and therapy method) were selected. The AUC of the combined model was 0.867. There was no significant difference in the AUC between the combined model and the best radiomics model (<jats:italic>P<\/jats:italic>\u2009=\u20090.573). Decision curve analysis demonstrated the nomogram has satisfactory predictive value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MRI-based radiomics analysis may serve as a promising and noninvasive tool to predict outcome of locoregional treatment in HCC patients, which will facilitate the individualized follow-up and further therapeutic strategies guidance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-023-01030-5","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:02:27Z","timestamp":1685466147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himeko","family":"Asayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"1030_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"1030_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1030_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1030_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"J Park","year":"2015","unstructured":"Park J, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155\u201366.","journal-title":"Liver Int"},{"key":"1030_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380.","journal-title":"Hepatology"},{"key":"1030_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9:682\u2013720.","journal-title":"Liver Cancer"},{"key":"1030_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3348\/kjr.2009.10.5.425","volume":"10","author":"SW Shin","year":"2009","unstructured":"Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10:425\u201334.","journal-title":"Korean J Radiol"},{"key":"1030_CR8","doi-asserted-by":"crossref","unstructured":"Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012.","DOI":"10.5402\/2012\/480650"},{"key":"1030_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","volume":"37","author":"JL Raoul","year":"2011","unstructured":"Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212\u201320.","journal-title":"Cancer Treat Rev"},{"key":"1030_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.dld.2011.06.016","volume":"43","author":"M Boulin","year":"2011","unstructured":"Boulin M, Ciboulet A, Guiu B, et al. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis. 2011;43:905\u201311.","journal-title":"Dig Liver Dis"},{"key":"1030_CR11","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1364\/BOE.9.003783","volume":"9","author":"H Lin","year":"2018","unstructured":"Lin H, Lin L, Wang G, et al. Label-free classification of hepatocellular-carcinoma grading using second harmonic generation microscopy. Biomed Opt Express. 2018;9:3783\u201393.","journal-title":"Biomed Opt Express"},{"key":"1030_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000365993","volume":"87","author":"S Ogasawara","year":"2014","unstructured":"Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87:330\u201341.","journal-title":"Oncology"},{"key":"1030_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000367743","volume":"4","author":"T Arizumi","year":"2015","unstructured":"Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4:253\u201362.","journal-title":"Liver Cancer"},{"key":"1030_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12880-022-00900-8","volume":"22","author":"ZW Li","year":"2022","unstructured":"Li ZW, Ren AH, Yang DW, et al. Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features. BMC Med Imaging. 2022;22:176.","journal-title":"BMC Med Imaging"},{"key":"1030_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00535-014-0973-8","volume":"50","author":"R Tateishi","year":"2015","unstructured":"Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350\u201360.","journal-title":"J Gastroenterol"},{"key":"1030_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1478-3231.2008.01957.x","volume":"29","author":"P Tandon","year":"2009","unstructured":"Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502\u201310.","journal-title":"Liver Int"},{"key":"1030_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00000478-200201000-00003","volume":"26","author":"GY Lauwers","year":"2002","unstructured":"Lauwers GY, Terris B, Balis UJ, International Cooperative Study Group on Hepatocellular Carcinoma, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2002;26:25\u201334.","journal-title":"Am J Surg Pathol"},{"key":"1030_CR18","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1007\/s00330-021-07910-0","volume":"31","author":"C Kong","year":"2021","unstructured":"Kong C, Zhao Z, Chen W, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol. 2021;31:7500\u201311.","journal-title":"Eur Radiol"},{"key":"1030_CR19","doi-asserted-by":"publisher","first-page":"582788","DOI":"10.3389\/fonc.2021.582788","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wang N, Wu J, et al. Radiomics analysis based on contrast-enhanced MRI for prediction of therapeutic response to transarterial chemoembolization in hepatocellular carcinoma. Front Oncol. 2021;11:582788.","journal-title":"Front Oncol"},{"key":"1030_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/jmri.27143","volume":"52","author":"Y Sun","year":"2020","unstructured":"Sun Y, Bai H, Xia W, et al. Predicting the outcome of transcatheter arterial embolization therapy for unresectable hepatocellular carcinoma based on radiomics of preoperative multiparameter MRI. J Magn Reson Imaging. 2020;52:1083\u201390.","journal-title":"J Magn Reson Imaging"},{"key":"1030_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.2214\/AJR.18.19507","volume":"211","author":"J Kim","year":"2018","unstructured":"Kim J, Choi SJ, Lee SH, et al. Predicting Survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using Radiomics. AJR Am J Roentgenol. 2018;211:1026\u201334.","journal-title":"AJR Am J Roentgenol"},{"key":"1030_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/JHC.S351077","volume":"9","author":"Y Dai","year":"2022","unstructured":"Dai Y, Jiang H, Feng ST, et al. Noninvasive imaging evaluation based on computed tomography of the efficacy of initial transarterial chemoembolization to predict outcome in patients with hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:273\u201388.","journal-title":"J Hepatocell Carcinoma"},{"key":"1030_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.diii.2022.01.009","volume":"107","author":"G Aujay","year":"2022","unstructured":"Aujay G, Etchegaray C, Blanc J, et al. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagn Interv Imaging. 2022;107:360\u20136.","journal-title":"Diagn Interv Imaging"},{"key":"1030_CR24","doi-asserted-by":"publisher","first-page":"110250","DOI":"10.1016\/j.ejrad.2022.110250","volume":"150","author":"A Bele\u00f9","year":"2022","unstructured":"Bele\u00f9 A, Autelitano D, Geraci L, et al. Radiofrequency ablation of hepatocellular carcinoma: CT texture analysis of the ablated area to predict local recurrence. Eur J Radiol. 2022;150:110250.","journal-title":"Eur J Radiol"},{"key":"1030_CR25","doi-asserted-by":"publisher","first-page":"109773","DOI":"10.1016\/j.ejrad.2021.109773","volume":"141","author":"FCR Staal","year":"2021","unstructured":"Staal FCR, Taghavi M, Reijd DJ, et al. Predicting local tumour progression after ablation for colorectal liver metastases: CT-based radiomics of the ablation zone. Eur J Radiol. 2021;141:109773.","journal-title":"Eur J Radiol"},{"key":"1030_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000512028","volume":"10","author":"M Chen","year":"2021","unstructured":"Chen M, Cao J, Hu J, et al. Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma. Liver Cancer. 2021;10:38\u201351.","journal-title":"Liver Cancer"},{"key":"1030_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00330-019-06318-1","volume":"30","author":"J Peng","year":"2020","unstructured":"Peng J, Kang S, Ning Z, et al. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. Eur Radiol. 2020;30:413\u201324.","journal-title":"Eur Radiol"},{"key":"1030_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/JHC.S316117","volume":"8","author":"Z Guo","year":"2021","unstructured":"Guo Z, Zhong N, Xu X, et al. Prediction of hepatocellular carcinoma response to transcatheter arterial chemoembolization: a real-world study based on non-contrast computed tomography radiomics and general image features. J Hepatocell Carcinoma. 2021;8:773\u201382.","journal-title":"J Hepatocell Carcinoma"},{"key":"1030_CR29","doi-asserted-by":"publisher","first-page":"e32584","DOI":"10.1097\/MD.0000000000032584","volume":"101","author":"X Yang","year":"2022","unstructured":"Yang X, Yuan C, Zhan Y, et al. Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram. Med (Baltim). 2022;101:e32584.","journal-title":"Med (Baltim)"},{"key":"1030_CR30","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00270-022-03221-z","volume":"45","author":"H Bai","year":"2022","unstructured":"Bai H, Meng S, Xiong C, et al. Preoperative CECT-based Radiomic signature for Predicting the response of Transarterial Chemoembolization (TACE) therapy in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2022;45:1524\u201333.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1007\/s00330-021-08493-6","volume":"32","author":"L Jiang","year":"2022","unstructured":"Jiang L, Wang S, Ai Z, et al. Development and external validation of a stability machine learning model to identify wake-up stroke onset time from MRI. Eur Radiol. 2022;32:3661\u20139.","journal-title":"Eur Radiol"},{"key":"1030_CR32","first-page":"2375","volume":"6","author":"Z Li","year":"2016","unstructured":"Li Z, Xue T, Chen X. Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE. Am J Cancer Res. 2016;6:2375\u201385.","journal-title":"Am J Cancer Res"},{"key":"1030_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1478-3231.2007.01550.x","volume":"27","author":"S Nagaoka","year":"2007","unstructured":"Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091\u20137.","journal-title":"Liver Int"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-023-01030-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-023-01030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:02:32Z","timestamp":1685466152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-023-01030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1186\/s12880-023-01030-5","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"2 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Beijing Friendship Hospital, Capital Medical University. All methods were carried out in accordance with relevant guidelines and regulations. The need for informed consent was waived by the ethics committee of Beijing Friendship Hospital, Capital Medical University, because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}